期刊文献+

试述转化医学的发展与实践 被引量:1

On the development and practice of translational medicine
下载PDF
导出
摘要 转化医学是连接基础研究与临床应用的创新研究模式,发展转化医学,促进成果转化,可为临床疾病的防、诊、治提供先进的理念和方法。本文围绕转化医学的发展和实践进行综述。 Translational medicine is an innovative research model that connects basic research and clinical application.The development of translational medicine and the promotion of the transformation of results can provide advanced concepts and methods for the prevention,diagnosis and treatment of clinical diseases.This article reviews the development and practice of translational medicine.
作者 阿依谢姆古丽·阿力马斯 温浩 Ayixiemuguli·Alimas;Wen Hao(State Key Laboratory of Pathogenesis,Prevention and Treatment of High Incidence Diseases in Central Asia,Urumqi 830011,Xinjiang,China;Xinjiang Key Laboratory of Echinococcosis,Urumqi 830011,Xinjiang,China;Clinical Medical Research Institute of Xinjiang Medical University,Prevention and Treatment of High Incidence Diseases in Central Asia,Urumqi 830011,Xinjiang,China)
出处 《生物医学转化》 2021年第3期93-98,共6页 Biomedical transformation
基金 教育部“长江学者和创新团队发展计划”(IRT1181) 国家自然科学基金项目(81160201) 省部共建中亚高发病成因与防治国家重点实验室开放课题青年项目(SKL-HIDCA-2021-57)。
关键词 研究模式 转化医学 临床应用 Research mode Translational medicine Clinical application
  • 相关文献

参考文献13

二级参考文献66

  • 1Tufts Center for the Study of Drug Development. Outlook 2010 [ EB/OL]. [2014 -03 - 28]. http://csdd, tufts, edu/files/up- loads/outlook-2010, pdf.
  • 2ARROWSM1TH J, MILLER P. Trial watch: phase I1 and phase llI attrition rates 2011 - 2012 [ J]. Nat Rev Drug discov, 2013, 12(8) : 569.
  • 3ZERHOUNI E. Turning the titanic[J]. Sci Transl Med, 2014, 6 (221) :221ed2.
  • 4Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework [ J]. Clin Pharmacol Ther, 2001, 69(3) : 89 -95.
  • 5MIZUARAI S, IRIE H, KOTANI H. Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in bio- marker-driven anti-tumor drug development [ J ]. Curt Mol Med,2010, 10(6) :596 -607.
  • 6CIUNCI CA, PERINI RF, AVADHANI AN, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetux- imab in patients with advanced cancer[ J]. Cancer, 2014, 120 (1):77-85.
  • 7U.S. FDA Guidance for Industry. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recom- mendations for Labeling [ EB/OL ]. [ 2014 - 03 - 28 ]. http :// www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatory- Information/Guidanees/UCM337169. pdf.
  • 8U.S. FDA Guidance for Industry. Investigators, and Reviewers Exploratory IND Studies [ EB/OL ]. [ 2014 - 03 - 281. http:// www. fda. gov/OHRMS/DOCKETS/98fr/2005d-O122-gd10001, pdf.
  • 9KAPLAN N, GARNER C, HAFKIN B. AFN-1252 in vitro ab- sorption studies and pharmaeokinetics following microdosing in healthy subjects[ J]. Eur J Pharm Sci, 2013,50(3 -4) :440 -446.
  • 10CHO DY, BAE SH, SHON JH, et al. High-sensitive LC-MS/ MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil[ J ]. J Sep Sci, 2013, 36 (5) :840 -848.

共引文献81

同被引文献13

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部